Pharmacogenetics of asthma: Where are we now?

Michael J. Larj, Eugene R. Bleecker

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations

Abstract

Pharmacogenetics adds value with improved clinical markers and increased ability to predict efficacy with greater clarity. This should lead to individualized and simplified dosing, improved efficacy with specific treatment, and enhanced safety. Improved patient response should lead to enhanced patient compliance. Many challenges remain ahead including ethical issues related to patient confidentiality, and banking of DNA. Regulatory issues and guidelines need to be discussed to establish reasonable boundaries. There is also a need for review of diagnosis and treatment combinations and Food and Drug Administration review of the process. Standards should be in place for prescription and diagnosis and the use of surrogate markers of efficacy. Legal issues including patents must be addressed, in addition to commercial issues concerning patient, physician, and managed care acceptance.

Original languageEnglish (US)
Pages (from-to)109-117
Number of pages9
JournalClinics in Chest Medicine
Volume27
Issue number1
DOIs
StatePublished - Mar 2006
Externally publishedYes

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Fingerprint

Dive into the research topics of 'Pharmacogenetics of asthma: Where are we now?'. Together they form a unique fingerprint.

Cite this